Acurx Pharmaceuticals, Inc. announced efficacy results from the Phase 2 clinical trial (Phase 2a segment and Phase 2b segment) of ibezapolstat for the treatment of C. difficile Infection (CDI). Kevin Garey, PharmD, MS, Professor and Chair, University of Houston College of Pharmacy, the Principal Investigator for microbiome aspects of the ibezapolstat clinical trial program and Acurx Scientific Advisory Board member stated: " These results confirm and extend data from the open-label component of the Phase 2 study and demonstrate the potent activity of ibezapolstat against C. difficile.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.19 USD | 0.00% | +7.35% | -42.82% |
Apr. 04 | Top Premarket Gainers | MT |
Mar. 19 | H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.82% | 34.51M | |
+0.54% | 42.86B | |
+12.17% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.80% | 25.15B | |
-23.61% | 18.63B | |
+28.06% | 12.37B | |
-3.43% | 11.92B | |
+6.92% | 11.21B |
- Stock Market
- Equities
- ACXP Stock
- News Acurx Pharmaceuticals, Inc.
- Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection